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To define whether age modifies the prognosis of patients
with chronic kidney disease (CKD) on nephrology care, we
prospectively followed patients with CKD who have been
receiving nephrology care in a clinic for 1 year or more. The
incidence of end-stage renal disease (ESRD), defined by the
occurrence of dialysis or transplant, or death without ESRD
was estimated by a competing-risk approach, and interactions
between age and risk factors tested in Cox models over a
median follow-up period of 62.4 months. Of 1248 patients
with stage III–V CKD, 481 were younger than 65, 410 were
between 65 and 75, and 357 were over 75 years old. Within
each age class, the mean estimated glomerular filtration rate
(eGFR) was 31, 32, and 29ml/min per 1.73m2, respectively.
There were 394 ESRD events and 353 deaths. The risk of ESRD
was higher than the risk of death without ESRD for ageso60
years, and independent of eGFR. The ESRD risk diminished
with aging but still prevailed for eGFRs of 25–35 in patients
between 65 and 75 years and with an eGFR below 15 in those
up to 85 years old. Proteinuria significantly increased the risk
of ESRD with advancing age. Surprisingly, the unfavorable
effects of cardiovascular disease on ESRD and of diabetes
on survival significantly decreased with increasing age. Male
gender, higher phosphate, lower body mass index, and
hemoglobin were age-independent predictors for ESRD, while
cardiovascular disease, lower hemoglobin, higher proteinuria
and uric acid, and ESRD also predicted death. Thus, in older
patients on nephrology care, the risk of ESRD prevailed over
mortality even when eGFR was not severely impaired.
Proteinuria increases ESRD risk, while the predictive role of
other modifiable risk factors was unchanged compared with
younger patients.
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The prevalence of overt non-dialysis chronic kidney disease
(CKD), defined as an estimated glomerular filtration rate
(eGFR) o60ml/min per 1.73m2, is markedly high at older
ages.1–3 Prevalence of CKD stages III–IV in people aged 70–79
and 480 years was found equal to 32% and 61% in the
United States and 18% and 40% in Italy, respectively.4 It is
also estimated that the number of elderly patients with
treated end-stage renal disease (ESRD) has almost doubled
in the past 25 years.2,3 More important, non-dialysis elderly
patients have become prevalent also in nephrology clinics.5–9
The latter epidemiological finding is critical for three reasons.
First, nephrologists represent the main reference of care for
patients with overt non-dialysis CKD. Second, the number of
elderly patients referred to nephrologist has significantly grown
in the past decade.9 Third, patients followed in the nephrology
setting are worldwide characterized by more advanced renal
disease and higher burden of cardiovascular (CV) comorbidities
as compared with unreferred patients.5–7,10–14
In spite of the changing epidemiology of non-dialysis
CKD in nephrology clinics, no prognostic information has
been so far provided in the elderly patients under nephrology
care. This gap of knowledge is particularly important because
many elderly patients, unreferred or newly referred to nephrology
clinics, do not follow an inexorable course to ESRD as they
die before.6,8,15-17 It is also still unknown whether and how
age influences the predictive role of other risk factors for
ESRD and death in referred as well as unreferred patients.
In 2003, we designed a multicenter prospective study to
gain information on prognosis and risk factors in adult stage
III–V CKD patients regularly attending Italian renal clinics.5
In this cohort, we have recently quantified the predictive role
or ig ina l a r t i c l e http://www.kidney-international.org
& 2012 International Society of Nephrology
Received 16 November 2011; revised 3 February 2012; accepted 14
February 2012; published online 23 May 2012
Correspondence: Luca De Nicola, Cattedra di Nefrologia - Dip. Geronto-
logia, Geriatria, Mal.Metabolismo, Seconda Universita` di Napoli, Piazza
Miraglia, 80131 Napoli, Italia. E-mail: luca.denicola@unina2.it
6See Supplementary Material for the complete list of TABLE Investigators.
482 Kidney International (2012) 82, 482–488
of uncontrolled (not-at-goal) risk factors.18 In this study, we
evaluate the specific effect of age on the competing risks of
ESRD and death, and tested all the potential interactions
between age and the main determinants of either outcome.
RESULTS
Characteristics of patients
In all, 1248 Caucasian patients were prospectively followed
from 2003 to death or May 2011. Median age was 67 years
(interquartile range: 58–76). Of these, 481 (38%) patients
wereo65 years old, 410 (33%) patients were between 65 and
75 years, and 357 (29%) patients were over 75 years. Table 1
describes the main features by age class at study visit. Median
(interquartile range) length of follow-up in the clinic before
the study visit was slightly shorter in very old patients;
however, the number of visits in the year preceding the study
start was not different among age classes. Aging was
associated with higher prevalence of diabetes and CV disease
(CVD). Nutritional status was adequate throughout the age
classes, as documented by mean values of body mass index
and serum albumin. Frequency of underlying nephropathy
differed between the three groups, with hypertensive nephro-
pathy being prevalent in older patients and glomerulo-
nephritis in younger patients. Aging was also associated with
higher systolic blood pressure, and lower hemoglobin (Hb)
and 24 h proteinuria.
Therapeutic regimens at study visit by age are reported in
Table 2. Aging was associated with a wider use of furosemide
Table 1 | Demographics and clinical features of patients at study visit by age class
Overall (n=1248) o65 years (n=481) 65–75 years (n=410) 475 years (n=357) P-value
Age (years) 67±14 53±10 71±3 81±5
Male gender (%) 57.5 58.2 56.6 57.4 0.887
Nephrology care (years) 2.6 (1.4–5.8) 2.8 (1.7–6.1) 2.7 (1.3–5.5) 2.4 (1.4–4.9) 0.014
Nephrology visits (n) 4 (2–5) 4 (2–6) 3 (2–5) 4 (2–5) 0.182
BMI (kg/m2) 27.3±4.6 27.2±5.2 28.0±4.4 26.6±3.9 0.0002
Albumin (g/dl) 3.9±0.5 4.0±0.5 3.9±0.5 4.0±0.5 0.268
Smokers (%) 10.0 12.3 8.5 8.7 0.111
Diabetes (%) 27.7 23.9 31.7 28.3 0.033
Previous CV event (%) 31.8 22.7 35.6 39.8 o0.0001
Renal disease (%) o0.0001
Hypertension 24.0 13.9 31.2 29.4
Diabetes 14.7 12.9 17.8 13.5
GN 13.0 22.4 8.0 5.9
IN/PKD 16.4 19.8 14.4 14.3
Other/unknown 31.9 31.0 28.5 36.3
Systolic BP (mmHg) 140±18 135±18 142±17 143±18 o0.0001
eGFR (ml/min per 1.73m2) 31±14 31±15 32±14 29±13 0.042
CKD stages II/IV/V (%) 48.8/36.0/15.2 50.9/33.3/15.8 50.0/35.6/14.4 44.6/40.1/15.4 0.303
Phosphate (mg/dl) 3.9±0.8 4.0±0.8 3.8±0.9 3.8±0.8 0.020
Hemoglobin (g/dl) 12.6±1.8 12.9±1.9 12.5±1.7 12.2±1.7 o0.0001
Uric acid (mg/dl) 6.2±1.7 6.3±1.6 6.1±1.7 6.1±1.8 0.358
Cholesterol (mg/dl) 199±40 203±43 197±38 195±37 0.028
Proteinuria (g/24 h) 0.57 (0.17–1.28) 0.70 (0.28–1.5) 0.43 (0.13–1.28) 0.53 (0.15–0.96) o0.0001
Abbreviations: BMI, body mass index; BP, systolic blood pressure; CV, cardiovascular; eGFR, glomerular filtration rate estimated by the 4-variable MDRD equation; GN,
glomerulonephritis; IQR, interquartile range; IN, interstitial nephritis; nephrology visits, number of visits in the clinic in the last year before the study start; PKD, autosomal
dominant polycystic kidney disease.
Values are mean (s.d.), median (IQR), or percent.
Table 2 | Therapeutic features of patients at study visit by age class
Overall (n=1248) o65 years (n=481) 65–75 years (n=410) 475 years (n=357) P-value
NaCl intake o100mmol/24 h (%) 20.6 19.0 21.6 21.8 0.620
Protein intake o0.8 g/kg per 24 h (%) 54.0 57.7 50.4 52.8 0.225
BP lowering drugs (average number
per patient)
2.16±1.13 2.08±1.15 2.25±1.11 2.19±1.11 0.070
ACEi or ARB (%) 71.8 74.0 72.9 67.5 0.097
ACEi+ARB (%) 5.5 8.3 4.2 3.4 0.003
CCB (%) 46.8 44.1 51.7 44.8 0.051
BB (%) 18.8 23.1 18.5 13.2 0.001
Furosemide (%) 37.4 26.6 38.3 51.0 o0.0001
Statin (%) 22.0 23.5 25.6 15.7 0.002
ESA (%) 12.4 9.1 9.1 20.7 o0.0001
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, b-blocker; BP, blood pressure; CCB, calcium channel blocker; ESA,
erythropoiesis-stimulating agents; IQR, interquartile range.
Values are mean (s.d.), median (IQR), or percent.
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and epoietin, whereas the use of b-blockers, statins, and
combined angiotensin-converting enzyme inhibitor-angiotensin
II receptor blocker therapy was less frequent in elderly people.
Adherence to dietary regimens did not differ by age class.
Overall median follow-up was 62.4 months; 394 ESRD
events (all started dialysis) and 353 deaths (250 in the absence
of ESRD) were observed. Overall death rates (per 100 patient-
year) in the three classes of age (o65, 65–75, and475) were
equal to 1.7 (95% confidence interval (CI) 1.3–2.3), 6.1 (95%
CI 5.1–7.4), and 14.5 (95% CI 12.6–16.7), respectively.
Corresponding rates (per 100 patient-year) of ESRD by age
were equal to 9.0 (95% CI 7.8–10.4), 7.3 (95% CI 6.1–8.8),
and 7.9 (95% CI 6.4–9.8), whereas rates of death without
ESRD were equal to 1.2 (95% CI 0.8–1.7), 5.2 (95% CI
4.2–6.5), and 12.6 (95% CI 10.7–14.9), respectively. Overall,
risk of ESRD exceeded mortality (Po0.0001).
Figure 1 shows the complex nonlinear relationship
between age and eGFR, and risk of first occurrence of ESRD
or death without ESRD by 5 years of follow-up. Boundary
line corresponds to equivalence of risks. The area above the
line corresponds to pairs of values of age and eGFR for which
the risk of death without ESRD overcomes risk of ESRD, the
reverse being true in the area below. It appears that for eGFR
435ml/min per 1.73m2, risk of death is greater in people
465 years; thereafter, the risk of ESRD increases with
decreasing eGFR and overcomes risk of death without ESRD
even in advanced age. Independent of eGFR, the risk of ESRD
was higher than the risk of death for ages o60 years.
Cumulative incidence curves of the competing risks over the
entire length of follow-up for specific eGFR and age values
are reported in the Supplementary Appendix (Supplementary
Figure S1 online).
Results from multivariable analyses about age as modifier
of determinants of ESRD are reported in Table 3. Male
gender, lower body mass index, lower Hb, and higher
phosphate levels increased the risk of ESRD independently of
age. Conversely, age interacted significantly with proteinuria
(P¼ 0.012) and CVD (P¼ 0.20). The complex interaction
between age and proteinuria is depicted in Figure 2. Higher
proteinuria significantly increased the risk of ESRD with
advancing age; however, the predictive role of proteinuria
diminished from stages III to V because of the contempora-
neous interaction between CKD stage and proteinuria
(P¼ 0.022). A negative interaction between age and CVD
was also disclosed; indeed, the unfavorable effect of CVD on
the risk of ESRD decreased at older age and virtually
disappeared in patients aged 475 years (Figure 3).
Results from multivariable analyses about age as risk
modifier of overall death are reported in Table 4. CVD, ESRD,
higher uric acid levels, and lower Hb increased the risk
independently of age, whereas, as already reported in a
previous paper,18 association between proteinuria and death
was nonlinear, with a decreased risk below 0.5 g/24 h and no
substantial increments above 0.5 g/24 h (Table 4). A negative
interaction between age and diabetes was observed
(P¼ 0.002) and is depicted in Figure 4. The unfavorable
effect of diabetes on the risk of death decreased with aging
and virtually disappeared in patients over 80 years.
Results from univariate analyses on ESRD and death are
reported in the Supplementary Appendix online.
DISCUSSION
This is the first study evaluating the modifying effect of age
on the competing risk of ESRD vs. death and on the
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Figure 1 |Relationship between competing risks of end-stage
renal disease (ESRD) and death without ESRD after 5 years by
age and estimated glomerular filtration rate (eGFR). Boundary
line identifies equal risks of ESRD and death: above the line, risk
of death overcomes risk of ESRD, while the opposite occurs
below the line.
Table 3 |Multivariable Cox model (HR and 95% CI) of
determinants of ESRD
HR (95% CI) P-value
Age (years) — 0.019
Male gender 1.32 (1.06–1.65) 0.015
BMI (kg/m2) 0.97 (0.95–0.99) 0.007
Diabetes 1.17 (0.92–1.49) 0.212
CVD — 0.010
Smoking 1.09 (0.78–1.51) 0.623
Systolic BP (5mmHg) 1 (0.97–1.03) 0.876
Cholesterol (mg/dl) 1.00 (1.00–1.00) 0.507
Uric acid (mg/dl) 0.95 (0.89–1.01) 0.080
Hemoglobin (g/dl) 0.93 (0.87–1.00) 0.043
Phosphate (mg/dl) 1.25 (1.10–1.42) 0.0008
Uprot (g/24 h) — 0.037
CKD stageUprot — 0.022
AgeUprot — 0.012
AgeCVD — 0.020
Abbreviations: BMI, body mass index; BP, blood pressure; CI, confidence interval;
CKD, chronic kidney disease; CVD, cardiovascular disease; ESRD, end-stage renal
disease; HR, hazard ratio; Uprot, 24 h proteinuria.
Model is stratified for CKD stage and center.
Restricted cubic splines were used for Uprot and for CKD stage*Uprot (see Statistical
analysis).
The interaction between CKD stage and Uprot indicates that the predictive role of
Uprot decreases from stage III to V. HRs of interactions of age with Uprot and CVD
are depicted in Figures 2 and 3, respectively.
Only significant interactions with age were retained.
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predictive role of the main risk factors in a cohort of
patients with non-dialysis CKD under stable nephrology
care.
In our cohort, the rate of combined end point of ESRD
and death without ESRD more than doubled in patients over
75 as compared with younger patients, and this risk excess
went along with a steep increase of death. Age modified the
risks of the two competing end points depending on the
eGFR level (Figure 1 and Supplementary Figure S1 online).
Indeed, while the risk for ESRD overcame death risk
independently from eGFR up to 60 years of age, the risk of
death without ESRD tended to prevail at older age strata.
However, ESRD still represented the more frequent outcome
not only in elderly patients with kidney failure (stage V), but
also in those with less severe kidney disease, as it was the case
in patients in the 65–75 years stratum with eGFR in the
20–35ml/min per 1.73m2 range. These findings complement
the analysis by O’Hare et al,16 who compared the crude
incidence rates of ESRD and death in a large cohort of US
Veterans with CKD stages III–V. In that cohort, the incidence
of death was fivefold greater than that of ESRD, and the eGFR
thresholds marking a greater ESRD risk vs. mortality were
much lower than ours. In particular, in middle-aged patients
55 years
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Figure 2 |Adjusted hazard ratio (solid line) and 95% confidence intervals (dashed lines) of the interaction between age and
proteinuria in the prediction of end-stage renal disease (ESRD) by chronic kidney disease (CKD) stage (reference level of
proteinuria, 0.5 g/24 h). Hazard ratios were estimated at three specific age values to properly describe the interaction effect. The horizontal
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Figure 3 |Adjusted hazard ratio (solid line) and 95%
confidence intervals (dashed line) of cardiovascular disease
by age value in the prediction of end-stage renal disease
(ESRD). The horizontal dotted line represents hazard ratio¼ 1.
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(45–65 years) rates of ESRD overcame mortality only if
eGFR was o30ml/min per 1.73m2, and the same occurred
for patients aged 65–75 years exclusively when eGFR was
o15ml/min per 1.73m2.
When comparing the two studies, the different settings
must be taken into account. Besides the obvious difference in
gender (US Veterans were predominantly males, while in our
cohort females were 41%), all our patients had been followed
in a nephrology clinic for at least 1 year before enrolment,
with four visits in the last year also in older patients, while, as
reported recently,19 more than one-third of old Veterans do
not receive nephrology care before dialysis, and among those
receiving predialysis care, 26% are seen by a nephrologist
only 3 months before starting dialysis. This difference is
crucial because prolonging the chronicity criterion for CKD
definition from 3 to 12 months excludes a substantial
number of patients, about 30% on average, with acute and
transitory renal dysfunction rather than true CKD, and,
moreover, it is associated with higher rates of ESRD and
lower mortality.20 The relevance of length and intensity of
nephrology care on prognosis of CKD in elderly is further
supported by the observation that death still represents the
most frequent outcome in old people newly referred to
nephrologist.6,8 We cannot exclude that nephrology care may
play a role per se; indeed, a recent study in a cohort of elderly
diabetic CKD patients pointed out that mortality rates abate
when patients are treated by nephrologists rather than other
specialists.21
The effect of age on the fate of CKD patients does not
represent the only critical issue in contemporary geriatric
nephrology research, and in clinical practice as well; attention
in fact has been recently drawn on the gaps of knowledge on
age-related differences in the mechanisms and pathways that
contribute to progression to ESRD and mortality.2 This
information is essential to better delineate risk profile, and
preliminary to the identification of therapeutic goals, in
elderly patients.8,16,22 In this study, we originally assessed the
effect of age on the role of the main recognized determinants
of either outcome. Indeed, no previous study has system-
atically evaluated the interaction of age with other risk factors
in the prediction of death and ESRD. We found that in the
early stages of CKD, the presence of higher proteinuria
significantly increased the risk of ESRD in older patients
(Figure 2). The explanation is not readily apparent; we can
only hypothesize that the kidney of elderly patients is more
vulnerable to the ‘nephrotoxic’ effects of proteinuria due to
the greater degree of renal fibrosis and ischemia.23–25 To our
knowledge, only one study has evaluated the impact of overt
proteinuria by age on ESRD in tertiary nephrology care.7
Authors found that overt proteinuria is associated with ESRD
also in elderly patients; however, their analysis is limited by
the low number of risk factors included in the Cox analysis,
the inconsistent definition of overt proteinuria, and, more
importantly, by the retrospective design and the small sample
size.
Findings of our study therefore extend to the risk of
ESRD, the major predictive role of proteinuria in elderly
that has been previously evidenced for the mortality risk in
the setting of general population or unreferred patients
where death represents the most frequent outcome.14,26
Overall our data lend support to the proposal of new trials
specifically addressing the question as to whether a more
intensive therapy with anti-renin–angiotensin system drugs
may improve the cardiorenal prognosis in old proteinuric
patients.27
In this study, age emerged also as a modifier of the
prognosis dictated by CV disease and diabetes. Indeed, likely
as a result of survival bias, the risk associated with these two
Table 4 |Multivariable Cox model (HR and 95% CI) of
determinants of death
HR (95% CI) P-value
Age (years) — o0.0001
Male gender 1.10 (0.87–1.40) 0.378
BMI (kg/m2) 0.99 (0.97–1.02) 0.651
Diabetes — 0.0004
CVD 1.35 (1.08–1.68) 0.010
Smoking 1.20 (0.83–1.72) 0.329
Systolic BP (5mmHg) 0.97 (0.94–1.00) 0.079
Cholesterol (mg/dl) 1.00 (1.00–1.00) 0.367
Uric acid (mg/dl) 1.07 (1.00–1.13) 0.037
Hemoglobin (g/dl) 0.94 (0.87–0.99) 0.014
Phosphate (mg/dl) 1.01 (0.87–1.18) 0.985
Proteinuria (g/24 h) 0.007
0.0 vs. 0.5 0.65 (0.46–0.91)
1.0 vs. 0.5 1.13 (0.98–1.30)
3.0 vs. 0.5 1.19 (0.84–1.69)
ESRD 1.52 (1.11–2.09) 0.010
Age diabetes — 0.002
Abbreviations: BMI, body mass index; BP, blood pressure; CI, confidence interval;
CKD, chronic kidney disease; CVD, cardiovascular disease; ESRD, end-stage renal
disease; HR, hazard ratio.
Model is stratified for CKD stage and center. ESRD was entered as a time-dependent
variable. Restricted cubic splines were used for proteinuria, see Statistical analysis.
HR of the interaction of age with diabetes is depicted in Figure 4. HRs for proteinuria
are derived from restricted cubic splines and estimated for specific values.
Only significant interactions with age were retained.
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Figure 4 |Adjusted hazard ratio (solid line) and 95% confi-
dence intervals (dashed lines) of diabetes by age value in the
prediction of death. The horizontal dotted line represents hazard
ratio¼ 1.
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main comorbidities was attenuated in elderly CKD patients.
Conversely, age did not affect the risk for ESRD associated
with a series of modifiable risk factors, including body mass
index and serum phosphate, or the risk of death associated
with serum uric acid and proteinuria, and the risk for both
outcomes associated with anemia. These results underscore
that in outpatient nephrology clinics, the prognostic role of the
above-mentioned risk factors holds true also at advanced age.
This study has strengths and limitations. Strengths are the
well-characterized study cohort composed by patients under
stable nephrology care, the long follow-up with the evalua-
tion of the ideal hard end points for nephrology studies, and
the systematic assessment of the commonly reported risk
factors as continuous variables. On the other hand, results
cannot be generalized to unreferred patients or to ethnic
groups other than Caucasians. A further limitation is that the
analysis of risk factors is based on a single data collection;
therefore, we cannot exclude effects due to changes over time
of the examined factors that we are unable to assess. Finally,
even though we included in the survival analysis several
determinants of outcome, the potential confounding of
residual (unmeasured) factors cannot be excluded.
In conclusion, in non-dialysis CKD patients on stable
nephrology care, (I) aging reduces the risk of ESRD vs. death,
but the effect is remarkably minor as compared with previous
analyses in patients extracted from general population where
mortality predominates; (II) the predictive role of risk factors
is selectively influenced by age, with the effect of proteinuria
on the risk of ESRD being more pronounced at older age; on
the other hand, the significant prognostic role of a number of
modifiable determinants of outcome, such as body mass
index, serum phosphate, and Hb for ESRD, and Hb, uric
acid, and proteinuria for mortality, persists in older patients.
These findings may help nephrologists in recognizing
which outcome is most important to the elderly CKD
patients they regularly see (also to predict future renal
replacement requirements), and at identifying the potential
areas of further therapeutic improvement in this large and
high-risk population.
MATERIALS AND METHODS
TABLE prospective observational study was performed in 25
outpatient nephrology clinics scattered throughout Italy. Study
design and methods have been detailed previously.5,18
Patients
All the consecutive patients attending the centers during a 9-month
period in 2003 were eligible if they had diagnosis of CKD, eGFRo60ml/
min per 1.73.m2 (no substitutive treatment), and first visit dating back
more than 1 year before the study start. Patients with acute kidney injury
during the 6 months preceding the study visit were excluded.
All patients gave informed consent to the protocol that was
approved by the local Ethical Committee.
Data collection
At the study visit, information was collected on demographic,
clinical and laboratory data, and medical history, including previous
CV event. The 24-h urine collection was also required, and
eventually repeated if the value of measured creatinine excretion
rate was outside the 60–140% range of the value calculated according
to Dwyer and Kenler.28 GFR was estimated by the 4-variable
Modification of Diet in Renal Disease study equation. Outcome
measures were ESRD (defined by occurrence of dialysis or renal
transplant) and death (without ESRD and overall). For this study,
follow-up expiration date was 31 May 2011.
Statistical analysis
Continuous variables were reported as mean and standard deviation
(s.d.) or median and interquartile range according to their distribu-
tion, as assessed by the Shapiro–Wilk test. Categorical variables
were reported as percentage. Age was analyzed as a continuous
variable, but it was categorized into three classes (o65, 65–75, and
over 75 years) only for descriptive purposes. Differences in
characteristics of the three age strata were tested by means of one-
way analysis of variance or Kruskal–Wallis (according to their
distribution) and Pearson’s w2 test for continuous and categorical
variables, respectively. Median follow-up was estimated by the
inverse Kaplan–Meier approach.29 CIs of rates of ESRD and overall
death were calculated assuming a Poisson distribution. Risks of
ESRD vs. death without ESRD in the whole cohort were compared
according to Kochar et al.30
The prognostic role of age and eGFR was investigated using as
outcome either ESRD or death without ESRD, the question being
‘Which of the two events, ESRD or death, is more likely to occur as
first event at specific combinations of age and eGFR?’ As, as first
event, ESRD and death without ESRD are mutually exclusive events,
we used the competing-risk approach31 by fitting a separate model
for either outcome according to Fine and Gray.32 Therefore, in this
analysis, only ESRD was considered for patients who eventually
experienced both events (ESRD and death). Age and eGFR were
entered as continuous covariates. Nonlinear association of the
covariates with outcomes was first evaluated by restricted cubic
splines according to Harrell et al.33 Four knots were defined ‘a priori’
for age (55, 65, 75, and 85 years) and for eGFR (15, 30, 40, and
50ml/min per 1.73m2). Evidence of nonlinearity, as assessed by
likelihood ratio test,33 was found for the association between eGFR
and ESRD; therefore, in the final models age entered as a linear
term, while restricted cubic splines was used for eGFR. The
coefficients for covariates derived from the two models and the
predicted cumulative incidence of the two outcomes at 5 years of
follow-up were finally used to estimate the pairs of values of age and
eGFR, where the cumulative incidence of ESRD exceeded the
cumulative incidence of death without ESRD.
We further investigated the modifying role of age on determi-
nants of ESRD and, alternatively, of overall death (i.e. irrespective
of ESRD), the question being ‘Does age modulate the risk
of determinants on ESRD (or death)?’ Two multivariable Cox
proportional-hazard models, for ESRD and death, stratified by CKD
stage and center, were therefore used to estimate hazard ratios and
95% CI. Interactions between age and all the other covariates were
tested in turn and the significant ones (Po0.05) were retained in the
final models. Consistently with previous findings,18 the interaction
between CKD stage and proteinuria was forced into the model when
predicting ESRD, and the nonlinear association between proteinuria
and either outcome was taken into account by using restricted cubic
splines with four knots placed a priori at clinically relevant values
(0, 0.5, 1, and 3 g/24 h of proteinuria). When evaluating overall
survival, ESRD was included as time-dependent covariate; when
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evaluating time to ESRD, dead subjects were censored at the date
of death.
Data were analyzed using SAS version 9.2 (SAS, Cary, NC) and
R version 2.9.2 (R Foundation for Statistical Computing, Vienna,
Austria) software packages.
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